Business Progress - The company announced on February 11, 2026, that its subsidiary Tianxin Pharmaceutical and its branch Baiyunshan Pharmaceutical Factory have 24 products, including Cefuroxime Sodium for Injection, proposed for selection in the national drug procurement program. The total sales revenue for these products is projected to be 798 million yuan in 2024, accounting for 1.06% of the company's revenue, and 550 million yuan in the first three quarters of 2025, accounting for 0.89% of revenue [1]. Subsidiary Development - On February 2 and 3, 2026, subsidiaries Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. received changes to their drug production licenses from the Guangdong Provincial Drug Administration, involving new production addresses or adjustments to production workshops aimed at improving production efficiency. However, this is expected to have no significant impact on current financials [2]. Product R&D Progress - On February 6, 2026, the company's subsidiary Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd. successfully passed the consistency evaluation of quality and efficacy for its Alfacalcidol Soft Capsules, which are used to treat calcium metabolism disorders [3]. Funding Movements - According to data disclosed on February 5, 2026, JPMorgan Chase increased its holdings in Baiyunshan H-shares by 360,600 shares at approximately 18.85 HKD per share on January 30, 2026, raising its ownership stake to 9.12%. Additionally, the company emphasized in its Q3 2025 report that it would continue to promote its dividend policy and capital operations, but the timing of related events should be confirmed with the latest announcements [4].

Core Viewpoint - The company, Luoxin Pharmaceutical, plans to acquire a 19.0526% stake in Beijing Luoxin Health Technology Co., Ltd. for 67.56 million yuan, increasing its ownership from 80.9474% to 100% [1] Group 1: Transaction Details - The acquisition is classified as a related party transaction since Chengdu Deyi holds more than 5% of Luoxin Pharmaceutical's shares [1] - The transaction price is based on an assessed value of 354.6 million yuan for the total equity of Beijing Health as of October 31, 2025, reflecting an increase of 538.57 million yuan [3] - The acquisition aims to optimize resource allocation and enhance operational decision-making efficiency, aligning with the company's long-term development strategy [3] Group 2: Financial Performance of Beijing Health - For the period from January to October 2025, Beijing Health reported a revenue of 63.87 million yuan, a 16.12% increase from the full-year revenue of 55.00 million yuan in 2024 [2] - The net profit for the same period was 8.18 million yuan, marking a turnaround from a loss of 15.41 million yuan in 2024 [2] - The net cash flow from operating activities was 1.98 million yuan, indicating a positive shift from negative cash flow in the previous year [2] Group 3: Company Financials and Challenges - Luoxin Pharmaceutical has faced significant losses over recent years, with net profits of -1.448 billion yuan, -639 million yuan, and -768 million yuan from 2022 to 2024, totaling approximately -2.855 billion yuan [5] - The company's revenue has declined from 6.478 billion yuan in 2021 to 2.647 billion yuan in 2024, although there was a slight recovery in 2024 [5] - The company anticipates a narrowed loss for the fiscal year 2025, projecting a net profit of between -340 million yuan and -250 million yuan [5]

Core Viewpoint - Recently, Luoxin Pharmaceutical (002793) announced plans to acquire a 19.0526% stake in Luoxin Health Technology (Beijing) Co., Ltd. from Chengdu Deyixinhua Equity Investment Partnership (Limited Partnership) for 67.56 million yuan, increasing its ownership from 80.9474% to 100% [1] Group 1 - The transaction is valued at 67.56 million yuan, corresponding to Chengdu Deyixin's paid-in capital of 67.37 million yuan [1] - The completion of this transaction will result in Luoxin Pharmaceutical holding a full 100% stake in Luoxin Health Technology [1] - This transaction is classified as a related party transaction, as Chengdu Deyixin and its concerted parties hold more than 5% of Luoxin Pharmaceutical's shares [1]

Group 1: Humanoid Robots in Shenzhen - Shenzhen-based company, Yuejiang Technology, has developed a humanoid robot capable of serving popcorn in cinemas, working up to 14 hours a day and selling over 1,000 cups daily without errors [1][2] - The robot's development faced challenges in coordination of its "eyes, brain, and hands," requiring precise environmental recognition and decision-making [1][2] - Yuejiang Technology has achieved a 90% self-research rate for key components and a 100% localization rate, marking a significant milestone in the humanoid robot industry in Shenzhen [2] Group 2: Green Chemical Innovations in Shanghai - Shanghai-based Kubei Chemical has developed a method to recycle waste wind turbine blades, turning epoxy resin into renewable materials and separating carbon fibers [3][4] - The company’s innovative approach addresses the global issue of wind turbine waste, which has traditionally been managed through environmentally harmful methods [3][4] - Kubei's recyclable epoxy resin has been recognized by the Ministry of Industry and Information Technology and has led to the production of the world's first recyclable carbon fiber blades [4] Group 3: Intelligent Manufacturing in Suzhou - Hengtong Optical Technology in Suzhou has implemented a digital factory utilizing AI and 5G technology, significantly reducing the need for manual labor in fiber production [5][6] - The factory's intelligent manufacturing control center manages the entire production process, ensuring efficiency and adaptability to environmental changes [6] - By 2025, Suzhou aims to achieve an industrial output value of 4.9 trillion yuan, with Hengtong exemplifying the city's embrace of AI in manufacturing [6] Group 4: Steel Industry Transformation in Rizhao - Rizhao Steel has adopted advanced ESP technology, reducing energy consumption by over 70% and CO2 emissions by 80% in steel production [12][13] - The company has established multiple innovation centers to overcome technological monopolies and enhance production efficiency [12][13] - AI technology has been integrated into the steel manufacturing process, improving operational efficiency and reducing human error [13] Group 5: Data Center Development in Ningxia - Ningxia Zhongwei has become a hub for data centers, with significant investments leading to the establishment of a robust infrastructure capable of handling massive data processing tasks [14][15] - The region's favorable climate allows for energy-efficient cooling solutions, reducing energy consumption by over 60% compared to traditional methods [14][15] - By 2025, the data center cluster in Zhongwei is expected to support a substantial increase in the information technology service industry [15] Group 6: Smart Manufacturing in Shanxi - Tianbao Technology in Shanxi has modernized its flange manufacturing process through digital and intelligent systems, significantly increasing production efficiency [17][18] - The company has achieved an 80% rate of CNC equipment utilization, enhancing the precision and monitoring of production processes [18] - The local government supports innovation and collaboration among enterprises to foster a new quality of production in traditional industries [18] Group 7: Intelligent Mining in Guizhou - The mining industry in Guizhou is undergoing a transformation with the introduction of intelligent machinery, improving safety and efficiency in coal extraction [19] - The implementation of smart monitoring systems allows for real-time data analysis and remote control of mining operations, enhancing operational safety [19] - Guizhou's initiative to upgrade coal mining technology aims to shift the industry's perception from hazardous to innovative and efficient [19]

Company Overview - Dongyang Sunshine Pharmaceutical (东阳光药) received approval for Fumaric Acid Vonoprazan Tablets on January 30, 2026, leading to stock price fluctuations influenced by product approval and market expectations regarding competition and profitability [1] - The company's core product, Oseltamivir Phosphate (可威), is expected to account for over 60% of revenue in the first half of 2025, but is projected to decline by 37.1% in 2024 due to procurement issues [4] Industry Analysis - The generic drug market is highly competitive, with 39 companies already approved for the same product and an additional 69 companies under review, indicating potential price wars and profit margin compression post-patent expiration [3] - Takeda Pharmaceutical currently holds a monopoly in the market, but its market share is expected to decline rapidly after the patent protection period ends on August 29, 2026, leading to downward pressure on generic drug prices [3] Financial Performance - The company's price-to-earnings ratio (TTM) is negative at -57.55, reflecting ongoing profitability challenges [4] - On February 12, during a stock price drop, trading volume surged to 20.49 million HKD, indicating increased market volatility and diverging opinions among investors [4] Market Trends - The biopharmaceutical sector has seen a decline, with the A-share biopharmaceutical index dropping by 3.52% over the past 20 days, while the Hong Kong Hang Seng Index fell by 1.72%, suggesting weak industry sentiment [5] - Over the last 20 trading days, southbound funds have seen a net reduction of 38,060 shares, indicating short-term pressure on capital [6]

Core Viewpoint - Deyuan Pharmaceutical's Q4 2025 profit exceeded expectations due to adjustments in new drug R&D priorities and effective cost reduction measures, but profit forecasts for 2026 and 2027 have been lowered due to potential price pressure from centralized procurement of the core product "Furuitong" [1] Group 1: Financial Performance - In 2025, Deyuan Pharmaceutical reported a revenue of 1.058 billion yuan, representing a year-on-year increase of 21.80%, and a net profit attributable to shareholders of 237 million yuan, up 33.87%, driven by sales growth of products like "Furuitong" and "Bokaiqing" [3] - The revised profit forecasts for 2026 and 2027 are 174 million yuan and 140 million yuan, respectively, down from previous estimates of 218 million yuan and 200 million yuan [1] Group 2: Stock Performance - Over the past five trading days (February 9 to 13, 2026), Deyuan Pharmaceutical's stock price has decreased by 0.96%, with a price of 35.19 yuan at the close on February 13, reflecting a single-day drop of 0.54% [2] - The financing balance has declined for eight consecutive days, with a reduction of 10 million yuan over the last five days, indicating a 12.12% decrease and rising risk aversion among leveraged funds [2] Group 3: Recent Events - On February 5, the company released its 2025 performance report, which became a focal point of market attention following a detailed analysis by Shenwan Securities on February 9 regarding the Q4 performance [3] - The innovative drug pipeline includes DYX116 (a tri-target GLP-1 peptide), which has completed Phase I clinical trials for diabetes indications and received IND approval for weight loss indications, with Phase II trials expected to start in the first half of 2026 [1]

其他常规事件如财务报告发布已基于2025年三季报数据（营收8.92亿元，归母净利润2496.35万元），但 无公开信息提示近期有重大股东大会或产品发布等计划。 以上内容基于公开资料整理，不构成投资建议。 经济观察网 根据通化金马（000766）在投资者互动平台的最新披露，公司研制的化学1类新药琥珀八氢 氨吖啶片已完成综合审评工作，并进入最后审评环节，这一进展可能成为近期值得关注的事件。该信息 由公司于2026年2月12日通过官方渠道确认。 业绩经营情况 ...

财报分析 公司2025年中期业绩显示经营效率提升，但该数据发布于2025年8月31日，非近期热点。报告期内研发 成本同比收窄35.6%至8875.8万元，亏损同比收窄48.79%至1.12亿元，管线包括11款候选药物。当前收 入主要依赖与丽珠医药的授权协议，商业化团队已初步搭建，为产品上市铺垫。 以上内容基于公开资料整理，不构成投资建议。 经济观察网同源康医药近期热点集中于核心产品进展及资本运作。2026年2月9日，公司宣布其自主研发 的甲磺酸艾多替尼片(TY-9591)新药上市申请(NDA)获国家药监局药审中心受理，该药针对非小细胞肺 癌脑转移，为首个新一代EGFR-TKI抑制剂，且已于2026年1月纳入优先审评程序，上市进程提速。公 司董事长吴豫生表示，该药国内峰值年销售额预估超50亿元，针对脑转移及L858R突变市场潜力显著。 此外，2026年2月11日，联交所批准公司H股全流通安排，涉及460.8万股非上市股份转换，有助于提升 股份流动性。 股票近期走势 近期股价呈现震荡态势。截至2026年2月13日收盘，股价报12.80港元，较2月9日收盘价12.86港元微跌 0.78%，区间振幅达7.52%。成交 ...

Core Insights - The company, Nocera Biopharma-U (688428), is making significant progress in clinical research, partnerships, and product commercialization in 2026. Clinical Development Progress - ICP-488 (highly selective TYK2 inhibitor) has completed patient enrollment for its Phase III clinical trial for psoriasis, with a total of 383 patients enrolled, marking a key clinical milestone [2] - Soficitinib (TYK2 inhibitor) has completed patient enrollment for its Phase III registration trial for moderate to severe atopic dermatitis, with accelerated trials for indications like vitiligo and nodular prurigo [2] - Obinutuzumab (BTK inhibitor) has completed its Phase III clinical study for idiopathic thrombocytopenic purpura (ITP) and is expected to submit a New Drug Application (NDA) in the first half of 2026; a Phase IIb study for systemic lupus erythematosus (SLE) has met its primary endpoint, with a Phase III trial set to begin soon [3] - BCL2 inhibitor (Mesutoclax/ICP-248) is advancing two registration Phase III clinical studies in the hematological malignancies field [3] Collaboration and International Expansion - The partnership with Zenas BioPharma, established in October 2025, plans to initiate a global Phase III clinical trial for Obinutuzumab targeting secondary progressive multiple sclerosis (SPMS) in the first quarter of 2026; Zenas will also advance two preclinical molecules from Nocera Biopharma into clinical stages in 2026. The total potential value of this collaboration exceeds $2 billion, including milestone payments and royalties [4] Commercialization and Product Pipeline - Newly approved drugs, Tansimod (Mingnuokai) and Zolbetuximab (Yinuoxin), which were approved in 2025, are now on the market and expected to contribute to revenue growth alongside Obinutuzumab. The new indications for Obinutuzumab (such as first-line treatment for CLL/SLL) are anticipated to drive continued sales growth [5] - The company achieved profitability for the first time in 2025, with revenue of approximately 2.37 billion yuan and a net profit of about 630 million yuan. Management indicates that the company will enter a phase of sustainable profitability starting in 2025, focusing on global expansion and pipeline diversification to solidify performance [5]

Core Viewpoint - HaiChuang Pharmaceutical (688302) has made significant progress in commercialization, medical insurance access, and research pipeline, with revenue growth and reduced losses as indicated in its performance forecast [1] Group 1: Project Advancement - The company announced on February 1, 2026, that its soft capsule production line for the anti-tumor drug has passed GMP compliance inspection, indicating the core product, Deuteroenzalutamide soft capsules, is now capable of large-scale production, completing the "R&D - Production - Sales" full industry chain [2] Group 2: Business Progress - Deuteroenzalutamide soft capsules were included in the national medical insurance catalog on December 2025, effective from January 1, 2026, which is expected to enhance patient accessibility through a "direct sales + agency" dual-track model; the product was previously approved for market launch in May 2025 and included in the CSCO Prostate Cancer Diagnosis and Treatment Guidelines [3] Group 3: Product Development Progress - The company is focusing on prostate cancer and metabolic diseases, with the oral AR PROTAC drug HP518 having completed Phase I clinical trials, while Phase II trials in China and combination therapy studies are ongoing; HP515, aimed at treating metabolic-associated fatty liver disease (MASH), has entered Phase II clinical trials, with preclinical data on its combination with GLP-1 presented at international conferences [4] Group 4: Performance and Operations - The 2025 performance forecast indicates the company expects revenue between 19 million and 22 million, representing a significant year-on-year increase, with losses narrowing by 24.81% to 37.34%, primarily due to the sales of Deuteroenzalutamide [5] Group 5: Institutional Research - In January 2026, the company hosted a research meeting with 29 institutions, including Foresight Investment and Western Securities, reflecting market interest in its innovative drug pipeline [6]